Advertisement

Moderna’s COVID-19 vaccine approved for kids 6-11 in Canada

Click to play video: 'Moderna says COVID-19 booster shot appears effective against Omicron variant'
Moderna says COVID-19 booster shot appears effective against Omicron variant
Moderna said on Monday that a booster dose of its COVID-19 vaccine appeared to be protective against the Omicron variant in laboratory testing. They said a 50 microgram booster dose increased neutralizing antibodies against the variant 37-fold, with a higher, 100-mcg dose driving antibody levels more than 80 times pre-boost levels. – Dec 20, 2021

Moderna Inc. said on Thursday Canada authorized its COVID-19 vaccine for use in children between 6 and 11 years of age.

The vaccine, branded Spikevax, was recently cleared for use among kids in the same age group in Australia and the European Union.

Moderna last year said its two-dose vaccine generated virus-neutralizing antibodies in children aged 6-11 years and safety was comparable to that seen in clinical trials of adolescents and adults.

The vaccine, based on messenger RNA (mRNA) technology, is approved in the United States for people aged 18 and above. The company is awaiting a decision from U.S. regulators on the use of its vaccine for children aged 12 through 17 years.

Story continues below advertisement

Rival Pfizer’s PFE.N COVID-19 shot is cleared in the United States for children as young as 5 years.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

Canada in August had authorized Moderna’s vaccine for adolescents.

(Reporting by Amruta Khandekar; Editing by Shinjini Ganguli)

Click to play video: 'NACI recommends longer interval between COVID-19 vaccine doses, Pfizer preferred over Moderna for Canadians aged 12-29'
NACI recommends longer interval between COVID-19 vaccine doses, Pfizer preferred over Moderna for Canadians aged 12-29

Sponsored content

AdChoices